Therapie der End-of-Dose-Fluktuationen: Notwendigkeit eines individualisierten Vorgehens

Paul Lingor; Joseph Claßen; Heinz Herbst; Alexander Storch; Peter Urban; Ingmar Wellach; Wolfgang H. Jost

doi:10.1055/a-0583-8460

Therapie der End-of-Dose-Fluktuationen: Notwendigkeit eines individualisierten Vorgehens

Translated title of the contribution: Treatment of end-of-dose fluctuations: The need for an individualized approach

Paul Lingor
, Joseph Claßen
, Heinz Herbst
, Alexander Storch
, Peter Urban
, Ingmar Wellach
, Wolfgang H. Jost

University Medical Center
University Hospital Leipzig
Neurozentrum Sophienstraße
Rostock University Medical Center
Asklepios Hospital Hamburg Barmbek
Hamburg Walddörfer
Parkinson-Klinik Ortenau

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with Parkinson's disease show a wide heterogeneity of symptoms and comorbidities, requiring individualized therapeutic strategies, particularly in advanced stages of the disease. This is reflected by the choice of different substance classes and drugs for the treatment of end-of-dose fluctuations. Each of these drugs offers a characteristic profile of effects and unwanted side-effects, which has to be taken into consideration. Replacement of a substance by an alternative drug under consideration, for instance, of healthcare economics is possible only to a limited extent, since therapeutic effects as well as tolerability in the individual patient must be taken into account.

Translated title of the contribution	Treatment of end-of-dose fluctuations: The need for an individualized approach
Original language	German
Pages (from-to)	S59-S62
Journal	Fortschritte der Neurologie Psychiatrie
Volume	86
Issue number	S01
DOIs	https://doi.org/10.1055/a-0583-8460
State	Published - 18 Jul 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1055/a-0583-8460

Cite this

@article{3b8b927b5bd54a979388aeed09dae3fe,

title = "Therapie der End-of-Dose-Fluktuationen: Notwendigkeit eines individualisierten Vorgehens",

abstract = "Patients with Parkinson's disease show a wide heterogeneity of symptoms and comorbidities, requiring individualized therapeutic strategies, particularly in advanced stages of the disease. This is reflected by the choice of different substance classes and drugs for the treatment of end-of-dose fluctuations. Each of these drugs offers a characteristic profile of effects and unwanted side-effects, which has to be taken into consideration. Replacement of a substance by an alternative drug under consideration, for instance, of healthcare economics is possible only to a limited extent, since therapeutic effects as well as tolerability in the individual patient must be taken into account.",

keywords = "Added value, Fluctuations, Individualized therapy, Parkinson's disease",

author = "Paul Lingor and Joseph Cla{\ss}en and Heinz Herbst and Alexander Storch and Peter Urban and Ingmar Wellach and Jost, \{Wolfgang H.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Georg Thieme Verlag KG Stuttgart.",

year = "2018",

month = jul,

day = "18",

doi = "10.1055/a-0583-8460",

language = "Deutsch",

volume = "86",

pages = "S59--S62",

journal = "Fortschritte der Neurologie Psychiatrie",

issn = "0720-4299",

publisher = "Georg Thieme Verlag",

number = "S01",

}

TY - JOUR

T1 - Therapie der End-of-Dose-Fluktuationen

T2 - Notwendigkeit eines individualisierten Vorgehens

AU - Lingor, Paul

AU - Claßen, Joseph

AU - Herbst, Heinz

AU - Storch, Alexander

AU - Urban, Peter

AU - Wellach, Ingmar

AU - Jost, Wolfgang H.

PY - 2018/7/18

Y1 - 2018/7/18

N2 - Patients with Parkinson's disease show a wide heterogeneity of symptoms and comorbidities, requiring individualized therapeutic strategies, particularly in advanced stages of the disease. This is reflected by the choice of different substance classes and drugs for the treatment of end-of-dose fluctuations. Each of these drugs offers a characteristic profile of effects and unwanted side-effects, which has to be taken into consideration. Replacement of a substance by an alternative drug under consideration, for instance, of healthcare economics is possible only to a limited extent, since therapeutic effects as well as tolerability in the individual patient must be taken into account.

AB - Patients with Parkinson's disease show a wide heterogeneity of symptoms and comorbidities, requiring individualized therapeutic strategies, particularly in advanced stages of the disease. This is reflected by the choice of different substance classes and drugs for the treatment of end-of-dose fluctuations. Each of these drugs offers a characteristic profile of effects and unwanted side-effects, which has to be taken into consideration. Replacement of a substance by an alternative drug under consideration, for instance, of healthcare economics is possible only to a limited extent, since therapeutic effects as well as tolerability in the individual patient must be taken into account.

KW - Added value

KW - Fluctuations

KW - Individualized therapy

KW - Parkinson's disease

UR - https://www.scopus.com/pages/publications/85050257305

U2 - 10.1055/a-0583-8460

DO - 10.1055/a-0583-8460

M3 - Artikel

C2 - 30021233

AN - SCOPUS:85050257305

SN - 0720-4299

VL - 86

SP - S59-S62

JO - Fortschritte der Neurologie Psychiatrie

JF - Fortschritte der Neurologie Psychiatrie

IS - S01

ER -

Therapie der End-of-Dose-Fluktuationen: Notwendigkeit eines individualisierten Vorgehens

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this